Live

China retaliated with 34% tariffs on US goods, while Trump vows his policies will 'never change.'

NasdaqCM - Nasdaq Real Time Price USD

Tempest Therapeutics, Inc. (TPST)

0.6500

-0.0685

(-9.53%)

As of 12:19:04 PM EDT. Market Open.

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for TPST

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Favourable Signals For Tempest Therapeutics: Numerous Insiders Acquired Stock

Favourable Signals For Tempest Therapeutics: Numerous Insiders Acquired Stock

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma

Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

ALLR Allarity Therapeutics, Inc.

0.7921

-3.58%

EYEN Eyenovia, Inc.

1.0120

-8.83%

ADTX Aditxt, Inc.

4.6650

-16.40%

CNSP CNS Pharmaceuticals, Inc.

1.0500

-7.08%

SLXN Silexion Therapeutics Corp

0.8802

-5.37%

ENTO Entero Therapeutics, Inc.

0.4501

+2.95%

TOVX Theriva Biologics, Inc.

1.0894

-7.68%

RNAZ TransCode Therapeutics, Inc.

0.3951

-14.52%

CDIO Cardio Diagnostics Holdings, Inc.

0.3377

+2.46%

ZVSA ZyVersa Therapeutics, Inc.

0.6097

-4.73%